AzurRx BioPharma Announces Participation in the Q2 Virtual Investor Summit

Delray Beach, Florida--(Newsfile Corp. - May 11, 2021) - AzurRx BioPharma (NASDAQ: AZRX) today announced that James Sapirstein, Chairman, President, and CEO will be attending the Q2 Virtual Investor Summit.

About AzurRx BioPharma

AzurRx BioPharma, Inc. (NASDAQ: AZRX) is a clinical stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. The Company has a pipeline of three gut-restricted GI assets. The lead therapeutic candidate is MS1819, a recombinant lipase for the treatment of exocrine pancreatic insufficiency (EPI) in patients with cystic fibrosis and chronic pancreatitis. AzurRx is also advancing two clinical programs using proprietary formulations of niclosamide, a pro-inflammatory pathway inhibitor; FW-1022, for COVID-19 GI infections and FW-420, for Grade 1 Immune Checkpoint Inhibitor-Associated Colitis and diarrhea in oncology patients. The Company is headquartered in Delray Beach, Florida with clinical operations in Hayward, California. For more information visit www.azurrx.com.

For further information:

AzurRx BioPharma
Martin Krusin
646-699-7855
mkrusin@azurrx.com

About the Investor Summit

The Investor Summit (formerly MicroCap Conference) is an exclusive, independent conference dedicated to connecting smallcap and microcap companies with qualified investors. The Q2 Investor Summit will take place virtually, featuring 80+ companies and over 300 institutional and retail investors.

To request complimentary investor registration: please visit our website at www.investorsummitgroup.com

Contact:
Sasha Murray at sasha@investorsummitgroup.com